Welcome to Targos

A Leader in Customer-Oriented Biomarker Services

Targos core service business is to provide highly standardized development and application of clinical biomarkers for the international pharmaceutical and diagnostic industry. The company has supported more than 100 international clinical trials since 1999, which have led to the successful approval of several targeted therapies and IVDs for our customers. The expert team of on-site clinical pathologists operates in a professional environment of project management, logistics, data and quality management. Targos also supports the introduction of new Companion Diagnostic assays into the market.

Targos is a fully GCP-compliant central laboratory that is inspected by the U.S. Food and Drug Administration (FDA). As of June 2013, Targos Molecular Pathology GmbH has met all applicable standards for accreditation and is accredited by the College of American Pathologists (CAP). As of January 2014 Targos is enrolled in the CLIA program.

Targos to Conduct a Short Course  at the USCAP Meeting in Boston, Massachusetts, U.S.A.
Course: Predictive Biomarkers: Lessons from Clinical Trials
Date: Wednesday, March 25, 2015
Time: 8:00am to 12:00pm

Click here to view

Professor Reinhard Büttner - CSO of Targos  discusses how his research into lung cancer is fuelling the translation of large-scale molecular tumour diagnostics and personalised treatment strategies into clinical practice
Click here to view

Dr Thomas Henkel – CEO of Targos 
shares his vision for the health-care industry of tomorrow with Leuphana University of Lüneburg, Germany.

Click here to view